Docetaxel in Hormone Refractory Prostate Cancer (HRPC)[Weekly or 3weekly TAX + Prednisone in HRPC]
Status:
Completed
Trial end date:
2006-03-01
Target enrollment:
Participant gender:
Summary
Primary objectives:
- To determine the response rate, measurable and non measurable, to Taxotere® in the
second line setting.
Secondary objectives:
- To evaluate the overall safety and toxicity of Taxotere®/prednisone combination as
second line therapy in HRPC
- To evaluate PSA response (PSA: Prostate Specific Antigen)
- To evaluate symptomatic response
- To evaluate Quality of life
- To evaluate patient safety of weekly versus q3 weekly regimens of Taxotere®.